News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.1 ...

Neoadjuvant and adjuvant therapy for early-stage breast cancer Research ... of adjuvant endocrine therapy are recommended to receive endocrine therapy alone or endocrine therapy plus targeted ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

“Importantly, the NCCN Guideline recommendation of ribociclib in this broad population reaffirms the importance of offering eligible patients with early breast cancer, including those with ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC ... In the trial, Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by ...

"Today, many people diagnosed with HR+/HER2- early breast cancer in Europe lack options beyond endocrine therapy to help ... Kisqali® (ribociclib) is a selective cyclin-dependent kinase inhibitor ...